TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
作者信息
Pena Eduardo, Ahmed Saeed
机构信息
Drug Dependence Treatment Center, VA Boston Healthcare System, Jamaica, Plain, MA, USA.
Boston Medical Center/VA Boston Healthcare System, Boston, MA, USA.
出版信息
Addiction. 2020 Oct;115(10):1978-1979. doi: 10.1111/add.15143. Epub 2020 Jul 1.
Abstract
摘要
相似文献
1
TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.是时候重新审视美国在新冠疫情期间针对阿片类药物使用障碍药物治疗的不均衡政策了。
Addiction. 2020 Oct;115(10):1978-1979. doi: 10.1111/add.15143. Epub 2020 Jul 1.
2
Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2).优化 COVID-19（SARS-CoV-2）期间阿片类药物使用障碍的药物治疗。
J Addict Med. 2020 Jul/Aug;14(4):e1-e3. doi: 10.1097/ADM.0000000000000678.
3
Challenges of methadone maintenance treatment during the COVID-19 epidemic in China: Policy and service recommendations.中国新冠疫情期间美沙酮维持治疗面临的挑战：政策与服务建议
Eur Neuropsychopharmacol. 2020 Jun;35:136-137. doi: 10.1016/j.euroneuro.2020.03.018. Epub 2020 Apr 13.
4
Opioid Use Disorder and COVID-19: Crashing of the Crises.阿片类药物使用障碍与 COVID-19：危机的碰撞。
J Addict Med. 2020 Jul/Aug;14(4):e6-e7. doi: 10.1097/ADM.0000000000000684.
5
Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.阿片类药物使用障碍的药物治疗和社区药房：在全国性流行和全球大流行期间扩大护理。
Subst Abus. 2020;41(3):269-274. doi: 10.1080/08897077.2020.1787300.
6
A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.针对患有阿片类物质使用障碍患者的新冠疫情基层医疗应对措施
J Rural Health. 2021 Jan;37(1):169-171. doi: 10.1111/jrh.12438. Epub 2020 Jun 2.
7
Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.利用药剂师在 COVID-19 大流行期间维持和扩大阿片类药物使用障碍的丁丙诺啡供应。
Am J Health Syst Pharm. 2021 Mar 18;78(7):613-618. doi: 10.1093/ajhp/zxab003.
8
Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.在澳大利亚新南威尔士州新冠疫情早期，拘留场所中丁丙诺啡长效注射剂（CAM2038）的快速推广。
Addiction. 2021 Feb;116(2):426-427. doi: 10.1111/add.15244. Epub 2020 Sep 21.
9
Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?新冠疫情的教训：我们终于准备好让阿片类药物治疗变得可及了吗？
J Subst Abuse Treat. 2020 Oct;117:108074. doi: 10.1016/j.jsat.2020.108074. Epub 2020 Jul 6.
10
Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.对谢勒等人（2014年）的评论：阿片类药物维持治疗中保留或不保留的开放性问题
Addiction. 2014 Jan;109(1):88-9. doi: 10.1111/add.12376.
引用本文的文献
1
State guidance and system changes related to COVID-19: Impact on opioid treatment programs.与2019冠状病毒病相关的国家指导方针和系统变化：对阿片类药物治疗项目的影响。
J Subst Use Addict Treat. 2024 Mar;158:209214. doi: 10.1016/j.josat.2023.209214. Epub 2023 Nov 30.
2
Opioid-Involved Overdose Vulnerability in Wyoming: Measuring Risk in a Rural Environment.怀俄明州阿片类药物相关药物过量易感性：在农村环境中衡量风险。
Subst Use Misuse. 2022;57(11):1720-1731. doi: 10.1080/10826084.2022.2112229. Epub 2022 Aug 17.
Zotero 插件